Algert Global LLC lifted its holdings in Juniper Pharmaceuticals Inc (NASDAQ:JNP) by 20.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 144,565 shares of the specialty pharmaceutical company’s stock after purchasing an additional 24,530 shares during the period. Algert Global LLC owned about 1.33% of Juniper Pharmaceuticals worth $658,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also made changes to their positions in JNP. Renaissance Technologies LLC increased its stake in shares of Juniper Pharmaceuticals by 21.7% in the 1st quarter. Renaissance Technologies LLC now owns 309,500 shares of the specialty pharmaceutical company’s stock valued at $1,470,000 after purchasing an additional 55,200 shares in the last quarter. Nationwide Fund Advisors increased its stake in shares of Juniper Pharmaceuticals by 5,500.0% in the 2nd quarter. Nationwide Fund Advisors now owns 56,000 shares of the specialty pharmaceutical company’s stock valued at $283,000 after purchasing an additional 55,000 shares in the last quarter. JW Asset Management LLC increased its stake in shares of Juniper Pharmaceuticals by 10.0% in the 2nd quarter. JW Asset Management LLC now owns 426,903 shares of the specialty pharmaceutical company’s stock valued at $2,156,000 after purchasing an additional 38,771 shares in the last quarter. Macquarie Group Ltd. purchased a new position in shares of Juniper Pharmaceuticals in the 3rd quarter valued at about $129,000. Finally, Goldman Sachs Group Inc. purchased a new position in shares of Juniper Pharmaceuticals in the 1st quarter valued at about $100,000. Hedge funds and other institutional investors own 36.39% of the company’s stock.
Shares of Juniper Pharmaceuticals Inc (NASDAQ:JNP) opened at $4.80 on Monday. The company has a quick ratio of 1.68, a current ratio of 2.00 and a debt-to-equity ratio of 0.08. Juniper Pharmaceuticals Inc has a twelve month low of $3.65 and a twelve month high of $6.10. The stock has a market capitalization of $52.05, a PE ratio of 7.50 and a beta of 0.03.
Several equities analysts recently weighed in on the company. ValuEngine lowered Juniper Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. HC Wainwright reiterated a “neutral” rating on shares of Juniper Pharmaceuticals in a report on Monday, November 6th. One research analyst has rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $23.00.
ILLEGAL ACTIVITY NOTICE: “Algert Global LLC Buys 24,530 Shares of Juniper Pharmaceuticals Inc (JNP)” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2017/12/18/algert-global-llc-buys-24530-shares-of-juniper-pharmaceuticals-inc-jnp.html.
About Juniper Pharmaceuticals
Juniper Pharmaceuticals, Inc is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product.
Want to see what other hedge funds are holding JNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Juniper Pharmaceuticals Inc (NASDAQ:JNP).
Receive News & Ratings for Juniper Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.